menu
    • menu
    [{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Staphylococcus epidermidis","moa":"SPINK5 gene","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Filaggrin","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Strain of Staphylococcus Epidermidis","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Closing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Closing of Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Screens First Patient for Phase 1b Trial of ATR-12 for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Receives FDA IND Clearance to Treat Skin Rash from EGFR Inhibitors","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-04","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Azitra \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Azitra \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Azitra

    Menu

    Azitra

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

                            Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.

                            Brand Name : ATR12-351

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 28, 2024

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-04

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azitra Receives FDA IND Clearance to Treat Skin Rash from EGFR Inhibitors

                            Details : ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain. It is being evaluated for the treatment of EGFRi-associated skin rash.

                            Brand Name : ATR-04

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 22, 2024

                            Lead Product(s) : ATR-04

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azitra Screens First Patient for Phase 1b Trial of ATR-12 for Netherton Syndrome

                            Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.

                            Brand Name : ATR12-351

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 20, 2024

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Azitra, Inc. Announces Closing of Public Offering

                            Details : The net proceeds will be used for the development of ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express and secrete an active fragment of the full-length protein LEKTI. which is evaluated for the treatment ...

                            Brand Name : ATR12-351

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 16, 2024

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Azitra, Inc. Announces Pricing of Public Offering

                            Details : The company intends to use the net proceeds for clinical trials and product development of ATR12-351 (ATR-12) for the treatment of Netherton Syndrome.

                            Brand Name : ATR12-351

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 13, 2024

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Azitra, Inc. Announces Closing of Initial Public Offering

                            Details : The company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.

                            Brand Name : ATR-12

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Strain of Staphylococcus Epidermidis

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Azitra, Inc. Announces Pricing of Initial Public Offering

                            Details : The Company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.

                            Brand Name : ATR-12

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 15, 2023

                            Lead Product(s) : Strain of Staphylococcus Epidermidis

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : ThinkEquity

                            Deal Size : $7.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-01

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Leaps by Bayer

                            Deal Size : $17.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra

                            Details : The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and co...

                            Brand Name : ATR-01

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 15, 2020

                            Lead Product(s) : ATR-01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Leaps by Bayer

                            Deal Size : $17.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Staphylococcus epidermidis

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Condi...

                            Details : The patent includes broad composition of matter claims that cover the Company’s engineered bacterial strain discovery platform, are central to its programs for treating skin diseases, and provide a significant barrier to entry for competitors.

                            Brand Name : ATR-04

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 07, 2020

                            Lead Product(s) : Recombinant Staphylococcus epidermidis

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Azitra

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton Syndrome

                            Details : If ATR-12 is approved, Azitra would be eligible to receive a priority review voucher, which can be used for priority review of a drug marketing application for another product being developed by the company.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 27, 2020

                            Lead Product(s) : ATR-12

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth